Close Menu

hypertriglyceridemia

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced new preclinical data demonstrating the delivery capabilities of its GalNAc conjugate technology in its hypercholesterolemia and hypertriglyceridemia programs.

The researchers identified an accumulation of rare variants in four genes identified by GWAS. They now plan to sequence more candidate genes using Sanger sequencing and, eventually, next-generation sequencing.

Using genome-wide association and targeted re-sequencing studies, a Canadian-led research team has uncovered common and rare genetic variants in four genes that are over-represented in individuals with extremely high blood triglyceride levels.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.